

531,002

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 April 2004 (29.04.2004)

PCT

(10) International Publication Number
WO 2004/035769 A1

(51) International Patent Classification⁷: C12N 9/02,
C07K 14/47, 14/195

Staffordshire ST5 5SP (GB). DJEHA, Hakim [DZ/GB];
6 Rookery Close, Nantwich, Cheshire, CW5 5SJ (GB).

(21) International Application Number:
PCT/GB2003/004388

(74) Agent: GODDARD, David, John; Harrison Goddard
Foote, Orlando House, 11c Compstall Road, Marple
Bridge, Stockport SK6 5HH (GB).

(22) International Filing Date: 10 October 2003 (10.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0223696.6 14 October 2002 (14.10.2002) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*): ML LAB-
ORATORIES PLC [GB/GB]; 17 Hanover Square, Lon-
don W1S 1HU (GB).


(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): LIPINSKI, Kai,
Stefan [DE/GB]; ML Laboratories PLC, The Stephenson
Building, Keele University, The Science Park, Keele,

[Continued on next page]

(54) Title: IMPROVED IMMUNOTHERAPY



(57) Abstract: The invention provides an improved method of inducing an immune response against targeted cells. Using gene therapy to express both a toxin or prodrug converting enzyme as a means of killing a targeted cell type and also stress response protein (in particular, a heat shock protein) enhances the subsequent immune response directed against such cells. The method is particularly applicable to inducing an immune response against cancer cells. Also provided are polynucleotides, products and vectors for use in such a method.

WO 2004/035769 A1



Declaration under Rule 4.17:

- *of inventorship (Rule 4.17(iv)) for US only*

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.